APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
Trial details
- Registry ID
- NCT03745716
- Drugs studied
- APR-246 + azacitidine, Azacitidine
TrialRedline tracks 3 clinical trials sponsored by Aprea Therapeutics: 1 Phase 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)NCT03745716 | APR-246 + azacitidine, Azacitidine | Completed | 2020-11-27Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantNCT03931291 | APR-246 | Completed | 2021-08-27Actual |
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246NCT03268382 | APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Completed | 2019-07-10Actual |
Names as written in the registry records.